We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Haematology Analyzer Prototype Tested for Field Malaria Surveillance

By LabMedica International staff writers
Posted on 15 Sep 2022
Print article
Image: The XN-31 hematology analyzer on which the prototype for malaria detection was based (Photo courtesy of Sysmex Corporation)
Image: The XN-31 hematology analyzer on which the prototype for malaria detection was based (Photo courtesy of Sysmex Corporation)

Simple and accurate diagnosis is a key component of malaria control programmes. Microscopy is the current gold standard, however it requires extensive training and the results largely rely on the skill of the microscopists.

Malaria rapid diagnostic tests (RDT) can be performed with minimal training and offer timely diagnosis, but results are not quantitative. Moreover, some Plasmodium falciparum parasites have evolved and can no longer be detected by existing RDT. Malaria kills about 500,000 people a year worldwide, and 90% of these deaths are in tropical Africa.

A team of Medical Scientists at the Osaka Metropolitan University (Osaka, Japan) working with their Kenyan counterparts conducted an observational cross-sectional study to compare the effects of blood sampling methods (venous versus capillary) and sample storage temperature and length on the performance of a prototype hematology analyzer in the detection of Plasmodium infections. Of 171 subjects enrolled in this study, 169 provided both venous and capillary blood samples for evaluation.

Capillary blood was used to prepare thick and thin blood smears for microscopic examination, and for RDT diagnosis using the SD Bioline Malaria Ag Pf/Pv RDT (Standard Diagnostics Inc., Gyeonggi-do, South Korea). Immediately after sampling, both capillary and venous blood samples were directly analyzed on the prototype XN-31p automated hematology analyzer (Sysmex Corporation, Kobe, Japan) using the low malaria (LM) mode. In LM mode, approximately 130 µL of blood is needed, although only 60 µL of the sample is used for analysis. For PCR diagnosis, DNA was extracted from a quartered blood spot (17.5 µL) using the QIAamp Blood Mini Kit (Qiagen, Hilden, Germany). PCR amplification of the Plasmodium mitochondrial cytochrome c oxidase III (cox3) gene was performed.

The scientists reported that the XN-31p, microscopy, RDT, and PCR detected 18, 16, 18, and 23 Plasmodium infections, respectively. One Plasmodium malariae infection was detected by microscopy while three Plasmodium ovale and one mixed infection of P. falciparum and P. malariae were detected by PCR. On the XN-31p, Plasmodium infections were detected in the same set of 18 samples using both capillary and venous blood; all were identified as P. falciparum except in one capillary blood sample where the species could not be specified.

Relative to PCR, the sensitivity and specificity of the XN-31p with capillary blood samples were 0.857 and 1.000, respectively. Short-term storage of capillary blood samples at chilled temperatures had no adverse impact on parasitaemia and complete blood counts (CBC) measured by the XN-31p.

The authors concluded that their study showed that in lieu of venous blood, capillary blood can be used directly without any pre-treatment or dilution for malaria diagnosis on the XN-31p automated hematology analyzer. Moreover, capillary blood can be stored at chilled temperature for up to 24 hours without adversely affecting malaria diagnostic and CBC results, broadening the appeal to utilize the XN-31p in a hub and spoke model as a rapid and accurate malaria diagnostic method for mass surveys and case confirmation in remote locations. The study was published on September 1, 2022 in the Malaria Journal.

Related Links:
Osaka Metropolitan University 
Standard Diagnostics Inc 
Sysmex Corporation 
Qiagen 

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TRAcP 5b Assay
TRAcP 5b (BoneTRAP) Assay
New
Luteinizing Hormone Assay
DRG LH-Serum ELISA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.